1-methyl-1,2,3,4-tetrahydrobenzo[b]azepin-5-one | 3749-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1-methyl-1,2,3,4-tetrahydrobenzo[b]azepin-5-one
• 英文别名: 1-methyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one；2,3,4,5-Tetrahydro-1-methyl-1-benzazepin-5-on；1-Methyl-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin；1-methyl-1,2,3,4-tetrahydro-benz[b]azepin-5-one；1-Methyl-1,2,3,4-tetrahydro-benz[b]azepin-5-on；1-methyl-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one；1-methyl-3,4-dihydro-2H-1-benzazepin-5-one
• CAS: 3749-11-9
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: GNNRHEHPHKLWHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methyl-1,2,3,4-tetrahydrobenzo[b]azepin-5-one 在 氢氧化钾 、 溴化氰 、 盐酸羟胺 、 水 、 一水合肼 、 sodium sulfate 、 三乙二醇 作用下， 生成 4,5,6,7-tetrahydro-azepino[3,2,1-hi]indole-1,2-dione
  参考文献：
  名称：

  The Synthesis of 1-Benzazepine Derivatives as Model Compounds Related to Apo-β-Erythroidine^1,2

  摘要：

  DOI：

  10.1021/ja01620a034
• 作为产物：
  描述：

  methyl 2-[(4-ethoxy-4-oxobutyl)(methyl)amino]benzoate 在 sodium 、 xylene 作用下， 生成 1-methyl-1,2,3,4-tetrahydrobenzo[b]azepin-5-one
  参考文献：
  名称：

  683.某些多环吲哚和喹啉衍生物的结构和性质。第十一部分。4：5：6：7-四氢-1-甲基-4-氧代-2：3-苯并ze庚因的衍生物

  摘要：

  DOI：

  10.1039/jr9580003377

文献信息

• A Cascade of Acid-Promoted C–O Bond Cleavage and Redox Reactions: From Oxa-Bridged Benzazepines to Benzazepinones
  作者：Yuewei Zhang、Fengzhi Yang、Lianyou Zheng、Qun Dang、Xu Bai

  DOI：10.1021/ol502971e

  日期：2014.12.5

  A sequence of C–O bond cleavage and redox reactions in oxa-bridged azepines was realized under acid promoted conditions. This protocol provides an atom-economical and straightforward approach to access benzo[b]azepin-5(2H)-ones in high yields. The formal synthesis of tolvaptan was achieved by exploiting this new transformation.

  在酸促进的条件下，在氧杂桥联的ze庚烷中实现了一系列的C–O键断裂和氧化还原反应。该协议提供了一种原子经济且直接的方法，可以高产率获得苯并[ b ] azepin-5（2 H）-。托伐普坦的正式合成是通过利用这一新的转化而实现的。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：BLUE OAK PHARMACEUTICALS INC

  公开号：WO2022204150A1

  公开（公告）日：2022-09-29

  The present disclosure provides compounds and pharmaceutical compositions thereof. Methods of making and using the compounds are also provided. The compounds can be used to modulate such as activate TAAR1 and can be used for the treatment, prevention, diagnosis and/or management of various CNS disorders.

  本公开提供化合物及其制药组合物。还提供制备和使用这些化合物的方法。这些化合物可以用于调节，例如激活TAAR1，并可用于治疗、预防、诊断和/或管理各种中枢神经系统疾病。
• Intramolecular Pd(0)-Catalyzed Reactions of (2-Iodoanilino)-aldehydes: A Joint Experimental–Computational Study
  作者：Daniel Solé、Francesco Mariani、Israel Fernández、Miguel A. Sierra

  DOI：10.1021/jo301924e

  日期：2012.11.16

  An extensive joint experimental-computational density functional theory (DFT) study has been carried out to gain insight into the factors that control the chemoselectivity (i.e., acylation vs alpha-arylation reaction) of palladium-catalyzed cyclizations of (2-iodoanilino)-aldehydes. To this end, the nature of the tethers joining the aniline nitrogen and the aldehyde moiety, different palladium precatalysts and reaction conditions (base and temperature), as well as different additives (mono- and bidendate ligands) has been explored. The adequate selection of these variables allows for the control of the selectivity of the process. Thus, (2-iodoanilino)-aldehydes generally lead to the formation of nucleophilic addition derived products when Cs2CO3/Et3N is used as base. In contrast, the use of stronger bases like (KOBu)-O-t (in the presence of PhOH) mainly forms alpha-arylation reaction products. The different reaction pathways leading to the experimentally observed reaction products have been studied by means of computational tools.
• US7273880B2
  申请人：——

  公开号：US7273880B2

  公开（公告）日：2007-09-25
• [EN] HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DU VRS
  申请人：ENANTA PHARM INC

  公开号：WO2017123884A1

  公开（公告）日：2017-07-20

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.